Meet Brad Hauser. The Titans of Aesthetics Series No. 1

Dr. Grant Stevens

Hello everyone and welcome back to the technology of Beauty. Where I have the opportunity to interview the movers and shakers of the beauty business, and I assure you today is no exception. My dear friend Brad Hauser is our guest today, and for the first time in years, he's actually not gainfully employed, so I can't tell you what company he's working for.

However, as you're gonna hear, he's newly on the board of another company, which we will talk. And we're gonna hear about all the other companies that he's worked with and for here in the next 30 minutes or so. So Brad, we'll start with this. Thank you for coming down. I know you had some issues at the airport, so thank you very much for joining us.

Brad Hauser

Absolutely. Grant, great to see you.

Dr. Grant Stevens

I've been trying to get you on this program for two years.

Brad Hauser

I understand. Now's the right time. It's a pleasure to be here and thank you so much for having me on the show.

Dr. Grant Stevens

It's a pleasure to have you. Now let's start with. Where'd you grow up and wait before you go, you may recognize him a little bit, even if you don't know him. We had his twin brother on before, and that's Brent Hauser today. This is Brad Hauser. They both went to this little university in Northern California called Stanford. We'll get to that a little bit later. Where'd you grow up?

Brad Hauser

Yeah, so I'll, I'll apologize in advance to your listeners that listen to Brent's show, cuz a lot of it's gonna be the same.

We grew up in Houston, Texas, so we had a, a great. Family experience with three boys. Brenda and I got to compete together in athletics. So we were both runners ran in high school and that led us to Stanford. And we went to Stanford because of running, but also because of the academics.

We knew running wouldn't last forever. So to get a degree from that university, we're both pre-med planned on going into sports medicine using our athletic background and mixing it with the biology. And then we got sucked up into the aesthetic industry. So we both ended running at Nike, went into early stage company, which ended up being reliant technologies with a Fraxel laser.

And that started us and now we're. 20 years later.

Dr. Grant Stevens

Okay, so we're gonna go back. I want to repeat that. So, so the first aesthetic company you were with Reliant. And that's Fraxel. And you guys may know a Fraxel or Fraxel Dual. The Fraxel the first fraction and laser, I'm pretty sure. And absolutely.

And that's where you started?

Brad Hauser

That technology came out of Mass General with Rox Anderson and De Man. And it was the first fractional technology on the market and Brent and I started at the ground floor. Brent was the fourth employee, and I think I was about the 10th employee. You'll hear that I've followed Brent to a couple companies, which.

May make him happy. Cool sculpting as well. We'll get to that.

Dr. Grant Stevens

Don't jump too fast. Gotta go slow here.

Brad Hauser

He was, he started very early on at Reliant doing a lot of the early clinical work. I was still running for about another year. I joined as the receptionist.

Dr. Grant Stevens

No way. Absolutely. Were you there when Dennis Condon was there?

Brad Hauser

I was there before Dennis Condon, and then I was there with Dennis and then after Dennis as well. But yeah, I I sat in the front lobby. I took the phone calls and that was my first role. I was very fortuitous, got to work with great innovators.

Linda Benedicta was yeah, one of the founders of Reliant. And. Has been a mentor for me on the R&D side my entire career. Still in contact with him. He's back taking physics in UC Santa Barbara.

Dr. Grant Stevens

And his name came up today on other, on other shows we recorded. Yeah, and I've worked with Len through many companies, as you know.

Brad Hauser

Well, he would, he was at Coherent. And he really, with the ultra pulse laser, which is still on the market, he was the general manager, coherent when that came out in 94. Amazing. But what, what he gave me was my responsibility was not only receptionist, but I took the notes in the senior leadership meeting, in the board meetings.

Oh. And I kept doing that for seven straight years. So my first seven years of my career, I got to see all of the executive decisions and all of the board meetings with the vc as well as the.

Dr. Grant Stevens

What a great opportunity. I'm so jealous, no wonder, you're so smart.

Brad Hauser

And that gave me, that gave me a tremendous amount of experience very early on the, I'll say that was a gift.

And then I moved into product management. So I grew up really with the Fraxel on the commercial side, taking all the strategy for the product as well as the clinical strategy for those first eight years until we got acquired by Solta or what became Solta Thermo.

Dr. Grant Stevens

So you were there when the Solta, when the acquisition happened in in Solta form, when, when Thermage came together with Fraxel. And that was after I coined the term Therma frax. And when we put together Fraxel and Thermage and they of course sued me for pr infringement. Both companies did. And I remember that. So but, but then we, I said, well, you guys should just come under one roof.

And I can remember telling Dennis that, and and Clint Carnell that. Absolutely. And I remember Clint coming to the office and threatening me during, not to use Thermo frax, but of course I kept using it.

Brad Hauser

It, it, it made a lot of strategic sense. Reliant in a sense with Fraxel stolen the market, still a great product.

One of my favorite products on the. The company actually I see as a failure. We had two failed IPOs. We pulled the day before your price, so I was involved in writing the S one and going through that entire process. So learned once again, a learning experience could not have been better.

And then two failed acquisitions before Ulta Thermage came in in 2008 and ended up purchasing it. But anyways, those two companies strategically made a lot of sense put together and I think, and they're still together, Nick, creation of Sulta and what it's been able to do by putting those two core technologies, both innovations, science-based.

That's what I think is key to getting successful company and product in the marketplace, is making sure that it's based in science and that the clinical foundation is really there.

Dr. Grant Stevens

That's right. You've always said that we're gonna get to that when we get to cool sculpting. So safety, efficacy, and then some makes sense financially, but safety and efficacy first things for sure.

Without that, you can't go anywhere. Absolutely. Sosta comes along, you have some bumps there, Solta, not you firstly, but the company does and so forth. Then where'd you go next?

Brad Hauser

So I made a decision. I ended up moving, which is will come up I think in the future here as as we talk, but I actually went from the commercial side to the R&D side inside of Soto.

I ran advanced development really from the strategy side of what products needed to come out next. And in my career I wanted to get a larger company experience and there was a product that was owned by Mey Lipos. And I had an opportunity to go run that program at Mey and really get the larger pharma company experience at the same time.

And who did you report to? So interesting. I came in on the commercial side reporting to Keith Sullivan, who was also at Reliant. But then quickly moved over to the R&D side under the cmo, Ira Lawrence. And I got to work not only in the LipoSonix program inside of a pharmaceutical company, being an R&D gave a lot more flexibility for strategy than on the commercial side.

There's a lot more restrictions and compliance on the commercial side. Sure. Which is why I moved over to R&D. But I also got to work on rest. And the lip indication, which was 2010, 11 timeframe. So learned a more expansion from the electro mechanical devices that I had been experienced so far.

Dr. Grant Stevens

Now was Jonah running the company? He was Jonah's been a guest too? I should probably, absolutely. Now I didn't know you were on the R&D side of salt. I'm just curious clear and. Were you part of that?

Brad Hauser

Absolutely. That was one of the last programs before I left which was heavily involved with Clint Carnell on commercial side.

Yeah. But yeah, I was the partner in there on the R&D side.

Dr. Grant Stevens

I didn't know that. That's fantastic. Okay, so you're at Medicis R&D then, and you did the Restylane lip. Then what happened?

Brad Hauser

We made the decision, the strategic decision to let go of LipoSonix. It just did not fit in that portfolio.

And there was also, even though I was junior and didn't have insight, we knew that Medicist was likely going to be sold as well. So I was in Scottsdale, Arizona, there's not much medical device in Scottsdale. So I came back to the Bay Area and worked for Cutera, came in on the R&D side. Kevin Connors was running the company at the time.

Engineer by training at Coherent. And I moved over to the commercial side. So when there was an.

Dr. Grant Stevens

You left the R&D and went to commercial. That's the Xeo platform, wasn't it?

Brad Hauser

The Xeo platform. And then when I came on board we did the X L V. Which is great. Probably 32.

As well as the Enlightened, which is the picosecond device. So it was really the first expansion beyond the xeo which I think has done well for Cutera and growing it and getting past that. Xeo's a perfect 1064 platform, but it needed more products in the portfolio course. So moved over from R&D and ran commercial.

So typically what I'll find in a company is. Heavily weighted towards engineering at the top, or leadership, I'll be on the commercial side. If it's heavily weighted towards commercial, I'll go to the R&D side, try to find the gaps and fill that void.

Dr. Grant Stevens

Okay. Now how did you then get to Zeltiq or was Zeltiq next?

Brad Hauser

Yeah, so I went from Cutera to Cool Sculpting. So obviously my twin brother was there. I knew a lot of the management. Came in under Zeltiq, under the commercial side and moved over and ran R&D.

Dr. Grant Stevens

I remember you running R&D, but you came initially under commercial, huh? I did. Was Zeltiq and Pleasant.

Brad Hauser

Pleasant. Pleasant 2013.

Dr. Grant Stevens

Interesting. And we worked together when you were doing the R&D state on Zeltiq for years until the acquisition by Allergen.

Brad Hauser

Absolutely. So I ended up running R&D. 2015 through the acquisition and then held onto it for another three and a half years until I left for Soliton.

Dr. Grant Stevens

Well, we're gonna get to that. Hold on. So during that time that you were at Zeltiq for those acquisition, was that 2020 or 2019?

Brad Hauser

2017. April of 17 was the Allergan acquisition. I met the Allergan. You have the Allergan acquisition in the May of 2020.

Dr. Grant Stevens

We're, give, give that, there's a lot of acquisitions here.

A lot of them. Done that. Seven for me. Get it up. Seven for me personally. Unbelievable. Seven. You've been through seven acquisitions? Seven.

Brad Hauser

Seven M&A activities on either side. Either acquiring something and running the integration or being acquired and running the integration.

Dr. Grant Stevens

That's unbelievable.

Okay, so you're at Zeltiq, you came out with the new product. A bunch of the new products, they're cool sculpting products that is and took 'em through the fda. When

Brad Hauser

I came in we mainly had the large abdominal applicator in the flank applicator. And plus the original Cool core, so three applicators and we, there was a big strategic decision of whether or not we use cold to get into other things.

The cold can obviously treat other things. Or do we really focus on body contouring and try to expand the applications in body contouring? And I think Mark Foley and the whole team. An outstanding decision to focus. And I think it took that focus to get the product development, to get to seven applicators, seven new indications and grow the company from what was 115 million to about 350 million.

Dr. Grant Stevens

And didn't you launch the advantage, the cool sculpting advantage?

Brad Hauser

Yeah, that was 2016. So we expanded to the size, which you did the work on the outer thigh. We also expanded obviously to the submental. Upper arms, bra fat, back fat, whole bunch of new areas which expanded the commercial utility.

Dr. Grant Stevens

So Allergan comes along and buys Zeltiq. And then you moved to Allergan.

Brad Hauser

Absolutely. That was a, a great learning experience. I just, I've been so fortunate in my career to be able to work for and learn from so many great aesthetic veterans. And Brent Saunders, who's also obviously been on your show was fantastic.

When he came in, he recognized that cool Golding was different than the rest of the Allergan portfolio. Obviously the C-Suite at Zeltiq moved on, but my twin brother and I got to run the cool sculpting business. Br ran the commercial side, and I ran the non-commercial side as general manager and head of R&D for three and a half years.

Dr. Grant Stevens

And there you worked for Allergan until what year? I remember when you left.

Brad Hauser

So AbbVie acquired Allergan in May of 2020 is when it closed. It got announced in 19. I ended up leaving six months after the acquisition from AbbVie and moved on to soluton, which I was on the board for while I was even at Allergan since 2018.

Dr. Grant Stevens

Okay. So Soliton's the next company, and he was on the board and then they appointed him CEO, is that right?

Brad Hauser

Yeah, it was November of 2020. Typical transition where a founder, scientist Chris Capelli, he's the inventor of the solid town technology. He came out of MD and he was leading that company and it was time past the clinical stage, got an FDA clearance and time to commercialize and they asked me to join as a commercial c o and we were public at the time, so that was a great once again, a great experience for me to learn the public side of a being a CEO and doing the investment community as well.

But we got two more FDA clearances while I was. And we thought we'd have to commercialize. But unfortunately, or fortunately, Allergan came in very early on and had a strategic interest and we ended up announcing the sale of the company in May of 2021.

Dr. Grant Stevens

Let's go back a little bit and let our listeners and viewers know a little bit about Soliton because they may not know absolutely the name of the technology and what it was intended to treat, at least in the aesthetic world.

Brad Hauser

Yeah, absolutely. So the technology itself is a shockwave technology. It's very different than the other devices that are in the space with shockwaves, in that it has very, very high peak pressure and a very, very short.

So the high peak pressure will actually be selective towards denser or stiffer materials in the skin. So originally what Chris? Envision was a treatment for tattoo removal. The ink particles, tattoo ink itself is stiffer or denser than the surrounding dermis. So as the sound wave is penetrating through the tissue, it speeds up and it causes a shearing effect.

And the pressures that it achieves 12 megapascals, which is about 1500 pounds per square. With a very, very short pulse, very steep rise time and fall time. Provides a sharp, cutting edge and it actually physically disrupts that material. So you see in the histology that the ink particles.

Or just obliterated or broken apart. What they realized over time was that those ink particles aren't cleared by the body because it doesn't create inflammation, it doesn't create heat, so there's no thermal or any type of significant wound healing response. That would then need to be needed to clear the ink particles.

So the macrophage has just come back in and regul the ink particles. It does lighten a tattoo, but it doesn't remove a tattoo. So what they ended up doing was using laser tattoo removal and using this in between because it also, the air bubbles themselves. Are broken apart by the technology. So you can actually do multiple laser passes if you use the soluton or, or was the brand name technology in between?

So tattoo removal is the first FDA indication that was achieved and it was using as an adjunctive therapy. Q switch laser for blacking tattoo. And during that time that they were getting the FDA clearance it was actually a physician that they showed the histology when they zoomed out from the ink particles, they saw the subcutaneous tissue and the fiber septa.

That are tethered down for cellulite, were just obliterated in the fat because the adipocytes in the fat is much less dense than the collagen fibers of fibro septa. So that's what triggered them to start looking at cellulite. And that really became the primary focus of the company with the non-invasive, completely noninvasive treatment of cellulite using the shockwave technology.

Dr. Grant Stevens

So the shockwave. Preferentially goes to denser tissue with a high energy short pulse wave would go to the fibro receptor that created the dimple.

Brad Hauser

Yes. The, the ones that are tethered down are, are tighter, are selectively treated, and it's not like it's a complete physical shearing, but at the microscopic level, you get shearing of the collagen fibers and over.

That tether loosens, so you get lessening of the dimple. As well as in the general dermis, you see overall new collagen being laid down. So the rippling effect, that's where I think it's really a home run is where you look at the rippling type of cellulite. Right, which we've talked for a few. You were the Wayne say, we only ripping Ripple, which is so difficult to treat.

There's just nothing out there that can treat it today. And I think that's where the technology shines. It does lessen the dimple, the, the depths of that dimple and the size of the dimple. But I think it's really that wavy skin quality of the thigh is where it shines.

Dr. Grant Stevens

Okay. So you got FDA approval for cellulite also, right?

Brad Hauser

So it's the only device. That non-invasive device that has a long-term improvement in the appearance of cellulite. It's not the same as the other devices that have a temporary improvement in the appearance of cellulite, which is really just physical manipulation. If you have vacuum, if you in any way a roller can have that same indication.

This is actually treating cellulite and has a long-term indication.

Dr. Grant Stevens

Now Avéli just got a long-term indication. So the Avéli device.

Brad Hauser

And so does laser laser assisted, which was Palomar's device. And Cellfina. But those break the skin surface. This is the only, that's what you meant. This is the only non-invasive technology that has that, all the other cellulite products that are non-invasive have a temporary reduction in the appearance of cellulite.

Dr. Grant Stevens

So Allergan was interested and they came in and bought that device, basically the restonic technology from soluton before the whole entity. The whole entity. Before you were commercial?

Brad Hauser

Yes. The deal, pretty much the deal was announced in May of 2021. And the first commercial product wasn't shipped until September.

Dr. Grant Stevens

So then did you go back to Allergan?

Brad Hauser

I did, I helped integrate the company for about seven months. Which integrations are always tough.

That's the hardest part of acquisitions is making sure the acquiring company gets the, the talent, but also the know-how to be able to run that company the way the business model was set up in the acquisition. And that's always the challenge. I think the trust that I built on both sides, having come from Allergan as well as having the entire team underneath me at Soluton really enabled us to integrate fairly quickly.

And I think Allergan has a great handle on that technology.

Dr. Grant Stevens

I would agree with that. I love that technology for ripples, especially for wavy, cellulite hips. So it's a fantastic oncology so. You took a little time off.

Brad Hauser

Well, that was only last month, so I'm taking some time off.

Dr. Grant Stevens

Right. And then you just recently announced on LinkedIn, you're on a new board.

Why don't you share with that? Share that with our guests or with our, viewers and listers. What company are you now on the board with? As of couple days ago.

Brad Hauser

Yeah, so last week I joined the board of Candescent Biomedical which is a, once again, what I look for when I'm looking at any company for employment or advising in any way, shape or form, is something that's unique and innovative.

That, once again, is based in science, has good people that can build a, a strong team and execute. I think those are the key things that are. And there's no doubt that the alkaline patch that candescent has to treat sweating or hyperhydrosis is completely innovative and has strong IP portfolio.

And their pivotal trial results are very good. And I think still in the FDA process, but hopeful that it'll go through that FDA process and through the De Novo process, get a clearance. And I think we'll make a strong impact to the physicians and patients.

Dr. Grant Stevens

How do you think that will fit into the aesthetic practice?

This is the technology of beauty. Tell me how you think Candescent and that patch will fit into the practices, the med spas, or wherever you see it fitting in.

Brad Hauser

Yeah, I think it has a large advantage of not having a capital component. I've, most of my career I've been involved with a capital component, but honestly, what we've done as strategy is try to figure out how to get pulled through and usage of that equipment.

It isn't just about selling that box, that's the old way of laser companies and. That does not work. Got these ups and downs when you have a new product and then everything goes down when it gets a little stale. So you have to have a business that is robust. Patients are coming in, you're helping get patients into the doctor's office, building, consumer awareness, those sorts of things.

So to me, I see this much more as a annuity stream, like a filler toxin or cosmoceutical. And I think the. Overactive Rin gland, hyperhydrosis heavy sweaters. People that are bothered is a fairly large market, and I think when you can get to the aesthetic patient and give them some relief of that, and it's not killing the RIN gland, but it is using a thermal reaction.

To Stu or limit sweating for a period of time. I think the studies showed that over three months you get a dramatic decrease in sweating, you get a decrease in odor. I think those are things that the aesthetic patient is looking for, and not only the ones that are clinically hyper hydrotic, but people that just are severely bothered by sweating.

Dr. Grant Stevens

What's your understanding regarding how long it takes for the treatment?

Brad Hauser

That's another thing. It's so easy to deliver. It's a patch that takes three minutes to deliver the heat, to get the clinical effect. So I think the, the company will need to make sure they do enough work. For the commercial launch, cuz clinical studies we all know are very well controlled.

But this should be a very, very straightforward, simple to use technology in the practice that can be delegated to staff as well.

Dr. Grant Stevens

Yeah, I couldn't agree with you more. I can't wait. I hope it gets FDA clearance and that we can utilize it for our patients who are troubled by sweating and who amongst us, doesn't wear anti aper prints or deodorants or that's, And the other nice thing is it can be an add-on to, a HydraFacial or cool sculpting or whatever you're doing.

You don't have to just do that, it's an add-on procedure. I can see it definitely I can see myself getting it when I get my HydraFacials.

Brad Hauser

So yeah, there's no reason that that patient that's in the office normally that is bothered by their sweating wouldn't continue. Have this treatment while they're getting their other regular maintenance treatments, whether or not they're HydraFacials, fillers, toxins, those sorts of things.

Dr. Grant Stevens

And my understanding it's four times a year. Is that your understanding also?

Brad Hauser

I think the clinic three months, the clinical data showed that it's lasts for three months. I think there will be a, a, it's an early technology. I think everyone wants answers right up front. I think the company will need to do the right things to work with physicians and understand when the right re-treatment path is, but the clinical results were sustained to three months.

Dr. Grant Stevens

Are you on any other boards at this point?

Brad Hauser

I am. I was elected to the board of a S L M S, American Society for Laser Medicine and Surgery. I'm the industry representative, elected for three years. But that's just a position that I think is important to be able to influence and give the A S L M S some guidance of how industry thinks so that they can build better program.

And also make sure that their members are educated about what the industry is doing and why.

Dr. Grant Stevens

Any other wards?

Brad Hauser

No, that's it.

Dr. Grant Stevens

So do you have any desire, interest in looking at other C-suite positions, running any companies? Are you just gonna ride off into the sunset or, oh, it's the future for you person?

Brad Hauser

No, unfortunately, it's a little early for me to ride off under the sunset.

Dr. Grant Stevens

Good. I was hoping that was the answer. I just didn't wanna assume anything.

Brad Hauser

I absolutely plan to take an operational role and actively networking, talking with, I know most of everybody in the industry, but I always wanna make sure, once again, it's, it comes down to the right technology.

Being founded in science and really working with a team that we can build something special. I think a lot of the things that I've got to work on are category creators and I want to keep that mentality and make sure that we're bringing new innovations to the market.

Dr. Grant Stevens

I'm certain you're gonna do that.

So you've been in this market, this, this, the beauty space, aesthetics since graduation, basically, and from that little institution and the Bay Area, we talked about. I noticed you brought your crystal ball with you. I'd like to know what you see over the next 3, 5, 10 years, and then I'm gonna ask you some specific questions.

But what, what do you think this aesthetic space, this beauty space will look like even in three years?

Brad Hauser

Yeah, I think we all wish we had a crystal ball right now with what's going on with the macroeconomic. So I, I do think that we're gonna see a little bit of slowdown and growth. I think the rebound, the good news is, is the pandemic and the rebound after the pandemic showed us that I think aesthetics is, the markets robust and it's gonna.

I don't think when 2008, 2009 hit, everyone was worried his aesthetics really gonna make it. They don't think there's any doubt. Aesthetics is here to stay. But whenever there's a slowdown in growth and people are looking at their wallet, I think the cost of money is higher. Right? So

smaller companies looking for funding, it's gonna be a little more challenging. I think that the ones, and I'm hopeful the, the ones that are truly innovative, And should get funding will continue to get funding. I think there's enough money and investment out there that they're looking for those things.

It's just gonna be that you're gonna have to show it and you're gonna have to prove clinically that the efficacy's there, the safety's there, and the market opportunities there. So I'm very hopeful that we're gonna see I think the, the last seven, eight years has been really good, which means people have been investing in R&D.

Yep. And I think that R&D work, the fruits are just coming out and I think there's a lot of new things out. And the best ones will make it maybe a little bit tough. Companies that are more mature are gonna have to be managed well through this period. But I do think, like I said, long term, I think the aesthetic mark is gonna continue to grow over time and these products will make it out.

Dr. Grant Stevens

So there's a couple things that keep coming up, but I'm curious if you have any comments on comments. One is exosomes. Any comments on exosomes?

Brad Hauser

I think it's very interesting. I think stem cells, exosomes is an area that this rejuvenation or really preventative aging. Is something we've been talking about with devices for a long time and I think this is probably a better approach to it.

It's not my direct expertise, but I think what I see is very encouraging and I think it's just a matter of how the agency. The FDA is going to regulate these and make sure that the safety and the claims and everything is, doesn't get too far ahead of itself. We have a tendency in a lot of areas of this space to jump way ahead from what we see in the lab and in early clinicals.

And obviously the FDA path is something that has to be considered.

Dr. Grant Stevens

Okay. How about subscription services? What are your thoughts about how that fits into the. The growth or the change in in the beauty market, the aesthetic space.

Brad Hauser

I think many of your guests have talked about how do you get access to the greater consumer.

They're, they're going into, when you think of a HydraFacial and you think of cosmeceuticals getting to that consumer earlier. Before they get into the doctor's office, I think is important. And I think price point is important there, and I think subscription models can really give access to a lot more patients.

So I think that is a positive. You just have to make sure you're getting into the right. Patient demographic, the ones that are gonna stay in the channel and not just look for that one good deal and get out of the channel. You're trying to get people in for the long term that we all wanna look as good as we feel.

That's what it comes down to. And we need to make it more affordable for more patients, cuz it is not today.

Dr. Grant Stevens

Okay. I'm a big fan of subscription. Also, I think it does make it more affordable, more attainable for many people. And we notice that the average age is going down. And men are expanding and the over percentage of women are expanding.

So obviously I'm very bullish on it. And I'd be remiss if I didn't ask you first of, I'll lay the foundation. There are a handful of neuromods on the market right now, and they're all, they're very similar to one another in terms of duration. There's one that's before the FDA right now. With a longer duration.

Do you think a longer duration, neuromodulator or neurotoxin will have a place in this market? And if so, how do you think it might affect the others in the same space? If you can answer that.

Brad Hauser

Yes. I'm, I can just shoot because I'm not an expert. By any means in, but you've watched the aesthetic space.

Watched the aesthetic space. I've watched. I do believe that revamps with their longer duration claim will be able to make an impact with the top end of the market. And I think my, there are other neuromodulators coming to the market.

Dr. Grant Stevens

We had one Flemming talked about the Galderma longer acting six month mantra. He just talked about it on the show.

Brad Hauser

So I think duration is gonna come into play and I think there will be other companies coming in as well. And, and I hope that the price point, that's what I'm most concerned about when you. Instead of three toxins on the market, when you have 5 67

that the, there, it doesn't become a, a low priced.

Dr. Grant Stevens

Like a race to the bottom.

Brad Hauser

Right. And we've been able to, cuz let's face it, I think a lot of this market is driven by toxins. And the success of tokin toxins and practice. So I'm just hopeful that that price point can stay up, cuz I think that will, that sets the bar for all aesthetics.

Dr. Grant Stevens

Okay. I would totally agree. And hopefully by the time we air this we'll have an answer and the answer will be a positive one for the fdu. For Revance. Any other things that we haven't. I'm trying to think. You, you've been a, a leader in this aesthetic industry and you and I have worked together for 20 years at least.

Oh, absolutely. It's, I appreciate it. Fantastic. And, and the experience you have both in the clinical as well as the R&D side is unmatched actually. It really is truly unmatched. I appreciate that and it's been such a pleasure to have you on this program and I look forward to seeing where you go.

And working with you. As you know, we've had a great time, great run on the number of companies.

Brad Hauser

Absolutely. What I would say in end, in ending is that all of my experience comes from the great leaders that I've worked for and worked with. And as much so as working with physicians that's what has kept me in this industry is the relationships with the not only key opinion leaders, but all the physicians in the aesthetic space.

And they're just willingness to share and wanna learn together. I think when industry and physicians come together, that's when you can make true innovation.

Dr. Grant Stevens

Well, it's been a ton of fun, hasn't it? Okay, well safe trip home to the Bay Area, and again, thank you very much for for joining us.

And I'd like to thank all of you for joining us today on this episode of The Technology of Beauty, where I have the opportunity to interview the movers and shakers of the beauty business. And as you just heard, Brad Hauser is a perfect mover and shaker. He is the quintessential example of a mover and shaker of the beauty business.

You take care, and I'll see you guys next Tuesday.